Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06958796

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) (SHIELD)

Exploratory Use of CMV Immunoglobulin in High Risk (D+R-) Transplant Recipients at the End of Antiviral Prophylaxis to Decrease the Risk of Late CMV Infection

Sponsor: Camille N. Kotton, MD

Conditions Cytomegalovirus Kidney Transplant; Complications Liver Transplant Complications Organ Transplant Simultaneous Liver-Kidney Transplantation; Complications

Interventions Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months

Updated 3 times since 2025 Last updated: Dec 18, 2025 Started: Nov 27, 2025 Primary completion: Dec 30, 2027 Completion: May 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06958796, this PHASE4 trial focuses on Cytomegalovirus and Kidney Transplant; Complications and remains actively recruiting participants. Sponsored by Camille N. Kotton, MD, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE4
Jun 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Camille N. Kotton, MD
Kamada, Ltd.
University of Texas Southwestern Medical Center

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Dallas, United States